​

Elevance Health (ELV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ELV Stock Forecast

Elevance Health (ELV) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $444.06, with a high of $498.00 and a low of $391.00. This represents a 11.45% increase from the last price of $398.45.

$350 $400 $450 $500 $550 $600 High: $498 Avg: $444.06 Low: $391 Last Closed Price: $398.45

ELV Stock Rating

Elevance Health stock's rating consensus is Buy, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (71.05%), 11 Hold (28.95%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 38 0 11 27 Strong Sell Sell Hold Buy Strong Buy

ELV Price Target Upside V Benchmarks

TypeNameUpside
StockElevance Health11.45%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Plans Stocks15.45%

Price Target Trends

1M3M12M
# Anlaysts-1955
Avg Price Target-$450.47$413.40
Last Closing Price$398.45$398.45$398.45
Upside/Downside-13.06%3.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 263127--22
Jul, 262128--22
Jun, 263127--22
May, 263118--22
Apr, 263118--22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 17, 2026Leerink Partners$395.00$369.286.96%-0.87%
Jul 16, 2026Bernstein$488.00$372.8530.88%22.47%
Jul 16, 2026New Street$482.00$377.6327.64%20.97%
Jul 16, 2026RBC Capital$424.00$390.338.63%6.41%
Jul 16, 2026Goldman Sachs$395.00$390.331.20%-0.87%
Jul 16, 2026Robert W. Baird$393.00$390.330.68%-1.37%
Jul 16, 2026Guggenheim$455.00$390.3316.57%14.19%
Jul 16, 2026Stephen BaxterWells Fargo$473.00$390.3321.18%18.71%
Jul 16, 2026Barclays$457.00$390.3317.08%14.69%
Jul 14, 2026Truist Financial$475.00$425.1711.72%19.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 16, 2026Goldman SachsNeutralNeutralhold
Jul 16, 2026GuggenheimBuyBuyhold
Jul 14, 2026Cowen & Co.BuyBuyhold
Jul 13, 2026Wells FargoOverweightOverweighthold
Jul 09, 2026RBC CapitalSector PerformSector Performhold
Jul 07, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 02, 2026BernsteinOutperformOutperformhold
May 26, 2026BarclaysOverweightOverweighthold
May 22, 2026UBSBuyBuyhold
May 20, 2026Deutsche BankHoldBuyupgrade

Financial Forecast

EPS Forecast

$20 $29 $38 $47 $56 $65 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$25.25$24.56$25.38$25.81$25.18----
Avg Forecast$25.94$29.02$33.07$33.21$34.49$39.12$45.09$53.01$60.81
High Forecast$26.78$29.93$33.17$33.39$35.31$43.70$46.79$55.16$63.27
Low Forecast$24.92$27.99$33.01$32.43$31.08$34.75$42.00$50.33$57.73
Surprise %-2.66%-15.37%-23.25%-22.28%-26.99%----

Revenue Forecast

$100B $140B $180B $220B $260B $300B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$138.64B$156.59B$171.34B$176.81B$199.13B----
Avg Forecast$137.85B$156.30B$170.38B$175.83B$191.75B$205.47B$221.23B$241.40B$279.48B
High Forecast$141.29B$160.07B$171.02B$177.24B$196.06B$217.15B$222.36B$248.91B$288.17B
Low Forecast$133.66B$152.01B$169.32B$174.23B$183.87B$194.40B$220.09B$232.01B$268.60B
Surprise %0.57%0.19%0.56%0.56%3.85%----

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$6.10B$5.89B$5.99B$5.98B$5.66B----
Avg Forecast$5.67B$6.08B$5.99B$7.67B$7.74B$9.14B$10.35B$12.36B$14.17B
High Forecast$6.81B$7.30B$7.18B$7.78B$8.23B$10.19B$10.91B$12.86B$14.75B
Low Forecast$4.54B$4.87B$4.79B$7.56B$7.24B$8.10B$9.79B$11.73B$13.46B
Surprise %7.56%-3.08%--22.05%-26.82%----

ELV Forecast FAQ

Is Elevance Health stock a buy?

Elevance Health stock has a consensus rating of Buy, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Elevance Health is a favorable investment for most analysts.

What is Elevance Health's price target?

Elevance Health's price target, set by 38 Wall Street analysts, averages $444.06 over the next 12 months. The price target range spans from $391 at the low end to $498 at the high end, suggesting a potential 11.45% change from the previous closing price of $398.45.

How does Elevance Health stock forecast compare to its benchmarks?

Elevance Health's stock forecast shows a 11.45% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the healthcare plans stocks industry (15.45%).

What is the breakdown of analyst ratings for Elevance Health over the past three months?

  • August 2026: 13.64% Strong Buy, 54.55% Buy, 31.82% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 9.09% Strong Buy, 54.55% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 13.64% Strong Buy, 54.55% Buy, 31.82% Hold, 0% Sell, 0% Strong Sell.

What is Elevance Health’s EPS forecast?

Elevance Health's average annual EPS forecast for its fiscal year ending in December 2026 is $39.12, marking a 55.36% increase from the reported $25.18 in 2025. Estimates for the following years are $45.09 in 2027, $53.01 in 2028, and $60.81 in 2029.

What is Elevance Health’s revenue forecast?

Elevance Health's average annual revenue forecast for its fiscal year ending in December 2026 is $205.47B, reflecting a 3.18% increase from the reported $199.12B in 2025. The forecast for 2027 is $221.23B, followed by $241.4B for 2028, and $279.48B for 2029.

What is Elevance Health’s net income forecast?

Elevance Health's net income forecast for the fiscal year ending in December 2026 stands at $9.14B, representing an 61.50% increase from the reported $5.66B in 2025. Projections indicate $10.35B in 2027, $12.36B in 2028, and $14.17B in 2029.